Breaking News on Pharmaceutical Technology
All news articles > April 2006
| « Previous month | Next month » |
28-Apr-2006
CSMA lets counterfeits surface
Surface technology firm CSMA has developed the only commercially available way of seeing the differences between drug tablets of the same composition that have been manufactured by two different routes.
BioProgress uses films in drug delivery
Speciality pharma company Bioprogress has launched new anti-snoring and caffeine products based on its edible film drug delivery technology, offering an effective alternative to conventional formulations.
EU carbon trading scheme may drive prices of raw materials up
The UK's chemical industry has given a cautious welcome to the government's national allocation plan (NAP) for Phase 2 of the EU Emissions Trading Scheme (ETS), warning pharma could see a rise in the price of active pharmaceutical ingredients (APIs) and intermediates.
Dalton invests big in oligos
Contract manufacturer Dalton has announced the completion of its oligonucleotide (oligos) manufacturing facility, in a $500,000 (€400,000) investment drive to dominate pilot and large-scale DNA and RNA oligo synthesis.
Merck's restructuring initiative costs dearly
Drug giant Merck & Co has seen flat sales and a rise in operating costs in the first quarter of 2006, as its restructuring initiative, which contract manufacturers welcomed, takes its toll on the company.
26-Apr-2006
Datalase marks success with expansion
Materials science firm Datalase has announced it has expanded its UK facility, targeting the pharmaceutical industry by applying its colour change technology in secondary packaging and on-product tablet marking.
Thermo finds right blend
Thermo has unveiled a new blend measurement solution for the real-time analysis of pharmaceutical blending processes in solid dosage form manufacturing which can be easily moved from blender to blender and used on any size pharmaceutical blender bin, from laboratory scale to production scale.
Lonza grows more self-reliant in China
Chemicals firm Lonza has vowed to spend $200m (€160m) over the next few years to expand in southern China, further limiting its dependence on external suppliers of intermediates and active pharmaceutical ingredients (APIs).
New asthma device moves closer to Europe
Bespak is now ramping up manufacturing of Chiesi Farmaceutici's new dry powder inhaler (DPI), in preparation for clinical trials of the device in patients with asthma and COPD (chronic obstructive pulmonary disease).
24-Apr-2006
Iron-metabolising enzyme key to Kaposi therapy
Scientists think that their latest discovery could result in the production of new drugs to treat Kaposi sarcoma tumour growth, which is the most frequent tumour in AIDS patients and is caused by infection of the patients with the Kaposi sarcoma-associated herpes virus.
Reaxa's prices down thanks to scale-up
British catalyst technologies firm Reaxa has slashed the prices of its encapsulated catalysts by two-thirds following increased demand for production scale quantities in pharma applications.
21-Apr-2006
GSK turns to RFID to protect its AIDS drug
GlaxoSmithKline (GSK) has begun distributing Trizivir tagged with radio frequency identification (RFID) technology as it intensifies efforts to combat counterfeiting.
Pulmonary drug delivery positioned for growth
The groundbreaking approval of Exubera signals that exciting times are ahead for the pulmonary route of drug delivery in many disease areas.
Another deal for Vectura's dry powder inhaler
British drug delivery firm Vectura has inked a deal with Boehringer Ingelheim to develop a dry powder inhaler (DPI) for a range of proprietary respiratory products of the German company, intensifying competition in a burgeoning asthma market.
Busak and Shamban set the sealing standard at Interphex
Silicone product provider Busak and Shamban, showcased a variety of solutions at this year's Interphex event, highlighting the stringent demands made by the pharma industry are met by its range of sealing and bearing products.
Lubrizol ditches API and intermediates unit
Determined to focus on its fuels and lubricant additives business, specialty chemical firm Lubrizol has sold its active pharmaceutical ingredient (API) and intermediate compounds division to Auctus, a German private equity firm.
19-Apr-2006
Vaccine manufacturing: The future is 'disposable'
As the threat of new viruses like avian influenza have heightened the need for greater speed and safety in vaccine production, single use technologies are proving far more safe and economic than traditional cleaning techniques, according to Pall's vaccine application development director.
Schering-Plough smells ViaNase potential
Kurve Technology has announced it has entered into a partnership with US pharmaceutical firm Schering-Plough involving its nasal drug delivery device which promises greater efficacy and efficiency than traditional devices such as spray pumps.
Agilent pursues RNA market
Agilent Technologies has stepped out of its comfort zone to pursue a new line of business in ribonucleic acid (RNA) production, with the recent acquisition of SynPro.
Invitrogen and Signalomics agree nanotechnology diagnostics deal
Invitrogen and Signalomics have agreed terms to develop nanotechnology-based laboratory approaches to cancer diagnostics in a move that is set to make the identification of tumours easier and quicker.
18-Apr-2006
Watson sees future in India
Watson Pharmaceuticals has acquired India's Sekhsaria Chemicals in a move to push forward its generic drug agenda.
12-Apr-2006
Lovenox dispute tests Momenta's nerves
Momenta, a US biotech company whose polysaccharide technology for the delivery and improved formulation of existing drugs promises lucrative revenues, is worried its generic version of Sanofi-Aventis's Lovenox may be in jeopardy after a US appeal court reinstated the drug's patent.
HollisterStier sees contract in Prism
HollisterStier has signed a deal to develop a process for compounding and fill/finishing PM101, Prism's acute care cardiovascular drug.
New approach to halt drug counterfeiting
ATS Automation Tooling has partnered with Tesa to launch a new marking technology to combat counterfeiting of glass drug products.
Microfluidics showcase nanoparticle products at Interphex
Nanoparticle product provider Microfluidics has used this year's Interphex show to introduce products based on its Microfluidizer processor technology, providing solutions for laboratory and manufacturing applications that use nanoparticle measurements.
New source of Tamiflu ingredient could boost production
American chemists have found that seeds of the sweetgum fruit contain significant amounts of shikimic acid, the main starting material for Tamiflu, in a discovery that could prove vital, as demand for the drug skyrockets amidst bird flu fears.
10-Apr-2006
NBC helps Onyvax out in cGMP contract with Eden
Thanks to a £2.7m (€3.9m) access fund from the UK's National Biomanufacturing Centre (NBC), biotech firm Onyvax has hired contract manufacturer organisation (CMO) Eden Biodesign to supply it with clinical current good manufacturing practice (cGMP) services for its cell vaccine programme in ovarian cancer, in the first contract at the site to have received public funding.
General Electric lights up Interphex
General Electric (GE) was out in force at Interphex, showcasing a range of new products and applications for pharma manufacturing.
Kasan at Interphex showcases industry standard kit
Screening and processing equipment supplier Kason, were out in force at InterPhex 2006, with a range of products that aid the manufacturing industry meet stringent pharmaceutical sanitary requirements.
Impinj brings UHF RFID to item level
Impinj showcased what it claims is the world's first application of ultra-high frequency (UHF) Gen 2 RFID technology for item-level tagging of pharma products.
First ADHD skin patch approved in the US
Shire, Britain's third-biggest drugmaker, has won approval in the US for Daytrana, a methylphenidate skin patch developed with Noven's transdermal technology, making it the first non-oral medication for the treatment of attention deficit hyperactivity disorder (ADHD) for children aged six to 12, in a market worth $200m (€165m) in sales per year.
07-Apr-2006
TransPharma pushes transdermal parathyroid hormone
Israel's TransPharma has announced the results of the first clinical trials of human Parathyroid Hormone 1-34 fragment (hPTH 1-34), delivered with its hand-held pen-size transdermal device, showed its system can systemically deliver effective therapeutic dosages, providing a painless, very low-cost, easy to use application.
Thermosafe Brands introduce Nomadic pallet shipper
ThermoSafe Brands has unveiled a pre-qualified, reusable shipping system, which enables the safe transportation of bulk quantities of pharmaceutical and vaccine substances under optimal temperatures.
BMS resorts to Puerto Rico for more biologics
US drug maker Bristol-Myers Squibb has said it will invest $200m (€166m) to expand its Puerto Rico facility, driven by a thirst for biologics that the firm is trying to quench, both in-house and through contract manufacturing.
Texas Instruments keeping RFID private
Texas Instruments used the recent Interphex show in New York to demonstrate its unique approach to improving the security of budding radio frequency identification (RFID) technology.
06-Apr-2006
UK regulator's suitability to investigate Parexel questioned
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has said it has so far found no evidence of wrongdoing in the human trials of the monoclonal antibody TGN1412, which US contract research firm Parexel carried out for German TeGenero, yet the agency's authority to carry out this investigation is undermined by a British parliamentary select committee report, published last year, which highlights flaws in the regulator that may have contributed to the disaster.
05-Apr-2006
Russian drug market soars 35 per cent to $9bn
The Russian pharmaceutical market is giving its rivals a run for their money, jumping 35 per cent in 2005 to $9bn (€7.3bn) - compared to 28 per cent growth in China and 37 per cent growth in Brazil - as foreign pharmaceutical manufacturers seek to localise their production, according to a report by Russian market research firm DSM Group .
Despite Katrina, Meco rides the storm at Interphex
Water purification company Meco, which was nearly destroyed in Hurricane Katrina's aftermath, showed at Interphex it can bounce back and showcased its latest products to In-PharmaTechnologist.com.
RFID software a 'Pandora's box'
The drug industry is becoming too complacent about the safety of radio frequency identification (RFID) according to new research.
BASF's new nanocoating 'triples production'
Chemical firm BASF has announced it has developed a new formulation for its Ibuprofen DC 85, an active substance in anti-inflammatory and analgesic products, using a nanocoating which, thanks to its resistance to high temperature, can increase production and reduce downtime.
Omnia clinches nanomedicine manufacturing contract
US biologics contract manufacturer Omnia Biologics has announced a master services agreement to provide drug development company Intradigm with process development and current good manufacturing practice (cGMP) services for cancer therapeutics delivered with a synthetic nanoparticle system.
03-Apr-2006
Millipore joins pilgrimage to Asia
US filtration giant Millipore is pumping more resources into its personnel and facilities in Asia, as outsourcing trends and new laboratory investments in emerging markets such as China and India are upping demand for its bioscience products and bioprocess services.
More patent armour for pharma
The damages caused by a patent dispute can sometimes wipe out the assets side of a company's balance sheet - a potential death sentence for small or medium companies - many of which aren't doing enough to protect themselves, according to a recent report by iPrex Solutions, an Indian-based provider of Intellectual Property Rights (IPR) services.
Scientists reveal new colorectal cancer mechanism
Scientists in the US have found out how the enzyme helps initiate the process that leads to colorectal cancer. Their discovery of a new molecular mechanism by which an enzyme promotes cancer spread may provide a new target at which to aim anti-metastasis drugs.
IMA becomes casualty of 'price war'
Italian packaging and processing machinery company IMA Group has posted a net profit of €13m for 2005, down 24 per cent from 2004, since a rise in revenues was offset by one-off charges, operating costs and a reduction in prices as the company tries to remain completive.
Single-use manufacturing gets united voice at Interphex
Manufacturers of single-use process components and systems within the biopharma industry in the US have launched a new alliance at Interphex to educate, standardise, and develop guidelines that safeguard the quality of drugs produced using their technology.
New moisture management service from Multisorb
Multisorb used the recent Interphex trade show to introduce its new range of consulting services to accompany its well-known range of sorbent products and save customers both time and money in drug packaging.
Nastech's results demonstrate RNAi potency for flu
Nastech Pharmaceuticals presents data demonstrating the effectiveness of its small interfering RNA (siRNA) therapeutics to target and inhibit influenza viral production, which is certain to have useful applications against current and future influenza strains.
| « Previous month | Next month » |
Sign up for your free newsletter
On-Demand Webinars, Videos, Audio
- POLYOX™ - New Applications in ER Matrices
Colorcon-CP-Pharma-2008 - Meet the requirements for GSDP for pharmaceutical products
SGS - Micro Reactors - The Future for Cost-Effective Manufacturing
DSM Pharmaceutical Products - Shoot for share: from vial to pre-filled syringe
Baxter - Increase your webinar performance with expert tips and advice
Decision News Media - Modern Chemical Development and cGMP Synthesis: When to use Chiral Chromatography
Novasep
Technical & Research papers
- SOTAX offers Upgrades for outdated Zymark TPW II and Prelude Models
Sotax AG - An Introduction to High-Potent API Classification
SAFC Pharma - SonoLab™ to Prosonitron® - Sonocrystallization Proven Across Scale
Prosonix - Making Better Medicines - Super Refined Excipients - Stability Enhancement and Topical Delivery of an API
Croda - Automated determination of active-substance content
Metrohm - Surface Dissolution Imaging Gives Insight Into Bioavailability
Paraytec Ltd - Increasing Demand for Fully Automated Dissolution Sinker Retrieval Prompts New Product Development
Sotax AG - The Twist N’Use – The economical plastic alternative to the glass ampoules.
Coradin - Ultrasonic Particle Engineering – The Key to Making Better MedicinesTM
Prosonix - Making Better Medicines - Solution for Automating Content Uniformity and Assay Testing
Sotax AG
Products, Brochures, Web links
- CD Linear, the linear tube filling machine according to CO.MA.DI.S.
IMA - Track & Trace solutions from the IMA Group
IMA - New Unica220 by Marchesini Group: versatile and ergonomic thermoformer
Marchesini Group Spa - The primary Dual Vials system – Keep Safe and preserve your active ingredient
Coradin - SPI Pharma: Formulating Success Through Innovation
SPI Pharma - Purac in the pharmaceutical industry
Purac Biochem bv - Derek for Windows
Lhasa Limited
Related sites
All Decision News Media Sites
Food & Beverage: Food & Beverage Development - Europe | Food & Beverage Development - North America | Food Marketing and Retailing | Food Processing & Packaging | Food Safety & Quality Control | Food and Beverage in Asia Pacific | Industrial Baking & Snacks | Beverage Technology & Markets | Confectionery & Biscuit Processing | Dairy Processing & Markets | Prepared Food and Meat Processing Nutrition: Supplements & Nutrition - Europe | Supplements & Nutrition - North America Pharmaceutical: Pharmaceutical Technology | Contract Research, Manufacturing & Clinical Trials Cosmetics: Cosmetics Formulation & Packaging - North America | Cosmetics Formulation & Packaging - Europe
© 2000/2009 - Decision News Media SAS - All right reserved.
